| Stage | Product | Partner |
 |
ARX788 αHER2 ADC – HER2+Breast Cancer(1) |  |
 |
ARX517 PSMA ADC - Oncology(2) | |
|
CD70 ADC - Oncology(3) | |
|
Bi-specific Anti-CD3 X Folate(4) | |
 |
ARX618 PEG-FGF21 – NASH |  |
 |
ARX720 Relaxin – Heart Failure | |
 |
Imrestor - Mastitis in Cattle(7) |  |
|
ADCs – Oncology |  |
|
Multi-Specific ADCs(9) | |
(1) Ambrx owns the worldwide rights to ARX788, with the exception of the People's Republic Of China, for which the rights to ARX788 have been licensed to Zhejiang Medicine Co., Ltd. (2) Potential indications include prostate cancer and glioblastoma multiforme. (3) Potential indications include renal cell carcinoma and nasopharyngeal carcinoma. (4) Potential indications include ovarian cancer. Ambrx owns the wordwide rights to this product candidate, with the exception of the, People's Republic Of China, for which the rights have been licensed to a collaborator. (8) Potential indications include oncology and autoimune/inflamatory diseases. |
| Key | Description |
|
Marketed |
|
Phase 2 |
|
Phase 1 |
|
Preclinical |
|
Discovery |
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed |
|
Ambrx ADC and Bi-Specific Product Candidates
|
|||||
|
|||||
|
|||||
|
|||||
|
Bi-specific Anti-CD3 X Folate(4)
|
|
||||
|
Collaboration Product and Product Candidates
|
|||||
|
ARX618 PEG-FGF21 – NASH
|
|
||||
|
ARX720 Relaxin – Heart Failure
|
|
||||
|
Imrestor - Mastitis in Cattle(6)
|
|
||||
|
Other Early-Stage Programs
|
|||||
 |
|||||
|
Multi-Specific ADCs(8)
|
|
||||
|
(1) Ambrx owns the worldwide rights to ARX788, with the exception of the People's Republic Of China, for which the rights to ARX788 have been licensed to Zhejiang Medicine Co., Ltd. (2) Potential indications include prostate cancer and glioblastoma multiforme. (3) Potential indications include renal cell carcinoma and nasopharyngeal carcinoma. (4) Potential indications include ovarian cancer. Ambrx owns the wordwide rights to this product candidate, with the exception of the, People's Republic Of China, for which the rights have been licensed to a collaborator. (6) Under this collaboration, Elanco Animal Health, a division of Eli Lilly & CO., has multiple projects directed at metabolic, infectious and inflamatory diseases in livestock and companion animals in early-stage clinical development, but we do not expect any of these other product candidates to launch before 2017. (8) Potential indications include hematologic and solid tumor cancers. |
|||||